Asia-Pacific Exosome Therapeutic Market - Industry Trends and Forecast to 2026

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 SECONDARY SOURCES

2.10 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES

3.1.2 INCREASING DEMAND FOR ANTI-AGING THERAPY’S

3.2 RESTRAINT

3.2.1 UNMET MEDICAL NEEDS

3.3 OPPORTUNITIES

3.3.1 PROGRESSING THERAPEUTIC VALUE OF EXOSOME

3.3.2 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES

3.3.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME

3.3.4 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS

3.3.5 RISING HEALTHCARE INFRASTRUCTURE

3.4 CHALLENGE

3.4.1 LACK OF SKILLED PROFESSIONAL’S REQUIRED FOR THE ISOLATION OF EXOSOME

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE

7 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TYPE

7.1 OVERVIEW

7.2 HYBRID EXOSOMES

7.3 NATURAL EXOSOMES

7.3.1 AUTOLOGOUS EXOSOMES

7.3.2 EXOGENOUS EXOSOMES

8 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY SOURCE

8.1 OVERVIEW

8.2 MESENCHYMAL STEM CELLS

8.3 DENDRITIC CELLS

8.4 BLOOD

8.4.1 B LYMPHOCYTES

8.4.2 OTHERS

8.5 BODY FLUIDS

8.5.1 SYNOVIAL FLUID

8.5.2 AMNIOTIC FLUID

8.5.3 SEMEN

8.5.4 OTHERS

8.6 MILK

8.7 SALIVA

8.8 URINE

8.9 OTHERS

9 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY THERAPY

9.1 OVERVIEW

9.2 CHEMOTHERAPY

9.3 IMMUNOTHERAPY

9.4 GENE THERAPY

10 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY

10.1 OVERVIEW

10.2 BIO MACROMOLECULES

10.2.1 NUCLEIC ACIDS

10.2.2 PEPTIDES

10.2.3 PROTEINS

10.3 SMALL MOLECULES

11 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.2.1 NON-SMALL CELL LUNG CANCER

11.2.2 BREAST CANCER

11.2.3 GASTRIC CANCER

11.2.4 HEAD AND NECK CANCER

11.2.5 OTHERS

11.3 CARDIAC DISORDERS

11.4 METABOLIC DISORDERS

11.5 NEUROLOGY

11.5.1 PARKINSON'S DISEASE

11.5.2 ALZHEIMER'S DISEASE

11.5.3 OTHERS

11.6 BLOOD DISORDERS

11.7 GYNECOLOGY DISORDERS

11.8 INFLAMMATORY DISORDERS

11.9 ORGAN TRANSPLANTATION

11.10 OTHERS

12 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.3 ORAL

13 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 RESEARCH & ACADEMIC INSTITUTES

13.4 DIAGNOSTIC CENTERS

14 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY

14.1 ASIA-PACIFIC

14.1.1 SOUTH KOREA

14.1.2 HONG KONG

14.1.3 AUSTRALIA

15 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 COMPANY PROFILE

16.1 STEM CELLS GROUP

16.1.1 COMPANY SNAPSHOT

16.1.2 PRODUCT PORTFOLIO

16.1.3 RECENT DEVELOPMENT

16.2 EXOCOBIO

16.2.1 COMPANY SNAPSHOT

16.2.2 PRODUCT PORTFOLIO

16.2.3 RECENT DEVELOPMENT

16.3 AEGLE THERPEUTICS

16.3.1 COMPANY SNAPSHOT

16.3.2 PIPELINE PORTFOLIO

16.4 AVALON GLOBOCARE CORP.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PIPELINE PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 CAPRICOR THERAPEUTICS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 CODIAK BIOSCIENCES

16.7.1 COMPANY SNAPSHOT

16.7.2 PIPELINE PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PIPELINE PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 EXOPHARM

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PIPELINE PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.10 EVOX THERAPEUTICS

16.10.1 COMPANY SNAPSHOT

16.10.2 PIPELINE PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 JAZZ PHARMACEUTICALS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 RENEURON GROUP PLC

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 UNITED THERAPEUTICS CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

UU

TABLE 1 EXOSOMES USED AS DRUG/GENE DELIVERY CARRIERS.

TABLE 2 COMPARISON OF CONVENTIONAL AND MICROFLUIDICS-BASEDEXOSOME ISOLATION TECHNIQUES

TABLE 3 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS

TABLE 4 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 5 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 6 ASIA-PACIFIC HYBRID EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 ASIA-PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 ASIA-PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 9 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 10 ASIA-PACIFIC MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 ASIA-PACIFIC DENDRITIC CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 12 ASIA-PACIFIC BLOOD IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 ASIA-PACIFIC BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 14 ASIA-PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 ASIA-PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 16 ASIA-PACIFIC MILK IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 ASIA-PACIFIC SALIVA IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 18 ASIA-PACIFIC URINE IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 ASIA-PACIFIC OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 21 ASIA-PACIFIC CHEMOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 ASIA-PACIFIC IMMUNOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 ASIA-PACIFIC GENE THERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 25 ASIA-PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 ASIA-PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 27 ASIA-PACIFIC SMALL MOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 28 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 29 ASIA-PACIFIC ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 ASIA-PACIFIC ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 31 ASIA-PACIFIC CARDIAC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 32 ASIA-PACIFIC METABOLIC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 ASIA-PACIFIC NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 34 ASIA-PACIFIC NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 35 ASIA-PACIFIC BLOOD DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 ASIA-PACIFIC GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 ASIA-PACIFIC INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 ASIA-PACIFIC ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 ASIA-PACIFIC OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 40 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 41 ASIA-PACIFIC PARENTERAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 ASIA-PACIFIC ORAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 44 ASIA-PACIFIC HOSPITALS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 45 ASIA-PACIFIC RESEARCH & ACADEMIC INSTITUTES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 46 ASIA-PACIFIC DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 47 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 48 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 49 ASIA-PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 50 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 51 ASIA-PACIFIC BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 52 ASIA-PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 53 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 54 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 55 ASIA-PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 56 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 57 ASIA-PACIFIC ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 58 ASIA-PACIFIC NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 59 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 60 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 61 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 62 SOUTH KOREA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 63 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 64 SOUTH KOREA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 65 SOUTH KOREA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 66 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 67 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 68 SOUTH KOREA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 69 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 70 SOUTH KOREA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 71 SOUTH KOREA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 72 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 73 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 74 HONG KONG EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 75 HONG KONG NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 76 HONG KONG EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 77 HONG KONG BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 78 HONG KONG BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 79 HONG KONG EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 80 HONG KONG EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 81 HONG KONG BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 82 HONG KONG EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 83 HONG KONG ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 84 HONG KONG NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 85 HONG KONG EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 86 HONG KONG EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 87 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 88 AUSTRALIA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 89 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 90 AUSTRALIA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 91 AUSTRALIA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)

TABLE 92 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)

TABLE 93 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 94 AUSTRALIA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)

TABLE 95 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 96 AUSTRALIA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 97 AUSTRALIA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)

TABLE 98 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 99 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)